20:35:21 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



NeutriSci International Inc
Symbol NU
Shares Issued 32,775,650
Close 2015-09-01 C$ 0.15
Market Cap C$ 4,916,348
Recent Sedar Documents

ORIGINAL: NeutriSci Announces National Distribution Agreement for NeuEnergy(TM) With Mass/Drug Retailer Rite-Aid

2015-09-03 08:33 ET - News Release

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/03/15

NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX VENTURE:NU) has announced a national distribution agreement for NeuEnergy(TM) with Pennsylvania based retailer, Rite-Aid Corporation ("Rite-Aid").

Rite-Aid is a Mass/Drug retail chain in the United States and a Fortune 500 company. Rite-Aid is the largest drugstore chain on the East Coast and the third largest drugstore chain in the U.S with 4,572 stores and annual sales exceeding $25 billion.

NeutriSci President Mr. Glen Rehman stated, "The addition of such a strong retail partner like Rite-Aid to our current distribution network further demonstrates the acceptance of NeuEnergy on a national level. We have worked hard to position ourselves with key retailers across the U.S. and Rite-Aid represents a national presence that will assist in establishing NeuEnergy as a major player in the energy and focus industry. We look forward to having NeuEnergy become available to Rite-Aid customers at their next product reset. It has been our goal to cause a disruptive change in the way consumers relate to energy products. Rite-Aid's decision to commit to NeuEnergy and NeutriSci further demonstrates industry belief in the product and its future growth."

NeuEnergy(TM) is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more, or to order NeuEnergy(TM), visit www.getneuenergy.com.

On Behalf of the Board of Directors of NEUTRISCI INTERNATIONAL INC.

Glen Rehman, President

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

About NeutriSci International Inc.: NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci has focused on the development of several breakthrough nutraceutical products with an initial focus on areas such as heart and cholesterol health, sleep deprivation therapies, immune defense as well as men's prostate and sexual health. NeutriSci continues to build strong relationships and distribution channels for its BluScience(TM) and NeuEnergy(TM) products with retailers throughout the United States. NeutriSci is focusing efforts in strengthening sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers. For more information, visit: www.neutrisci.com.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

Contacts:
Glen Rehman
President
NeutriSci International Inc.
(403) 264-6320
grehman@neutrisci.com

Investor Relations Contact:
KIN Communications Inc.
Fred Leigh, VP Investor Relations
1-866-684-6730

© 2024 Canjex Publishing Ltd. All rights reserved.